Below are the most recent publications written about "Receptors, Transferrin" by people in Profiles.
-
Parrow NL, Fleming RE. Transferrin receptor 1: keeper of HFE. Blood. 2023 01 26; 141(4):332-333.
-
Ginzburg YZ, Fleming RE. Tfr2 suppression benefits ?-thalassemic erythropoiesis. Blood. 2018 11 22; 132(21):2215-2216.
-
Li H, Choesang T, Bao W, Chen H, Feola M, Garcia-Santos D, Li J, Sun S, Follenzi A, Pham P, Liu J, Zhang J, Ponka P, An X, Mohandas N, Fleming RE, Rivella S, Li G, Ginzburg YZ. Decreasing TfR1 expression reverses anemia and hepcidin suppression in ?-thalassemic mice. Blood. 2017 03 16; 129(11):1514-1526.
-
Vujic Spasic M, Sparla R, Mleczko-Sanecka K, Migas MC, Breitkopf-Heinlein K, Dooley S, Vaulont S, Fleming RE, Muckenthaler MU. Smad6 and Smad7 are co-regulated with hepcidin in mouse models of iron overload. Biochim Biophys Acta. 2013 Jan; 1832(1):76-84.
-
Chen-Roetling J, Liu W, Regan RF. Iron accumulation and neurotoxicity in cortical cultures treated with holotransferrin. Free Radic Biol Med. 2011 Dec 01; 51(11):1966-74.
-
Corradini E, Rozier M, Meynard D, Odhiambo A, Lin HY, Feng Q, Migas MC, Britton RS, Babitt JL, Fleming RE. Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without transferrin receptor 2 or Hfe. Gastroenterology. 2011 Nov; 141(5):1907-14.
-
Swinkels DW, Fleming RE. Novel observations in hereditary hemochromatosis: potential implications for clinical strategies. Haematologica. 2011 Apr; 96(4):485-8.
-
Chua AC, Delima RD, Morgan EH, Herbison CE, Tirnitz-Parker JE, Graham RM, Fleming RE, Britton RS, Bacon BR, Olynyk JK, Trinder D. Iron uptake from plasma transferrin by a transferrin receptor 2 mutant mouse model of haemochromatosis. J Hepatol. 2010 Mar; 52(3):425-31.
-
H?nninen MM, Haapasalo J, Haapasalo H, Fleming RE, Britton RS, Bacon BR, Parkkila S. Expression of iron-related genes in human brain and brain tumors. BMC Neurosci. 2009 Apr 22; 10:36.
-
Fleming RE. Iron sensing as a partnership: HFE and transferrin receptor 2. Cell Metab. 2009 Mar; 9(3):211-2.